Are you Tharintorn Treesit?

Claim your profile

Publications (2)0.63 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Evaluate the efficacy of percutaneous radiofrequency ablation ofhepatic malignant tumors. An ultrasound-guided percutaneous radiofrequency ablation using a 17-gauge single needle perfusedcooled electrode (Cool-tip) RF ablation system was performed on 30 hepatic tumors in 26 patients between January 2009 and September 2010. The medical records, CT scan, and MRI results were assessed at one and three months after the procedure was completed. Primary technical success, local tumor progression, and complication were also evaluated. Twenty-six hepatic lesions in 23 patients were primarily hepatocellular carcinoma. Only four lesions in three patients were metastasized. Three of them were from colorectal cancer whilst another one was from malignant melanoma. At 1-month follow-up imaging post percutaneous radiofrequency ablation, complete ablation rate was 86.7%. Local tumor progression at 3-month follow-up imaging was 4.2%. The rate for minor complication was 3.8%. No major complication was found Complete ablation rate was found to increase signiJicantly in tumors size of less than 2 cm compared to those diameter larger than 2 cm (p < 0.05). Percutaneous radiofrequency ablation is one of the most effective and invulnerable therapeutic modality in treatment of hepatic malignant tumor. Size is the key factor of technical success as the smaller the size of tumor the better the outcome achieved.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet 01/2013; 96(1):77-82.
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to assess the diagnostic accuracy of ultrasonography (US)-guided core needle biopsy (CNB) for breast lesions. We performed US-guided CNB of 733 lesions in 674 women from January 2003 to December 2005. Surgical excision was performed on 331 lesions. We compared the histopathologic findings of the CNB specimens with those of surgical specimens or with patients' long-term follow-up images. We also calculated the agreement, underestimation, sensitivity and false-negative rates. The CNB results showed 334 breast cancers (46%), 28 high-risk lesions (5%) and 367 benign lesions (50%). Four (1%) lesions were categorised as inconclusive. The final diagnosis was breast cancer in 348 lesions. The kappa measure of agreement between the US-guided CNB results and surgical excision findings or follow-up results was 0.861 (p-value < 0.001). The underestimation rate was 40% (10 out of 25) for atypical ductal hyperplasia and 47% (14 out of 30) for ductal carcinoma in situ (DCIS). The CNB false negative rate and sensitivity for malignant lesions was 4% (14 out of 348) and 96% (334 out of 348), respectively. US-guided CNB is an accurate diagnostic alternative to surgical biopsy in patients with breast lesions detected via US, although the high underestimation rates in DCIS and high-risk lesions are still a concern.
    Singapore medical journal 01/2012; 53(1):40-5. · 0.63 Impact Factor